trial

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

NCTId NCT00089869

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

Phase 1, Phase 2 · Completed

Enrollment —

Design & status

Phase

Phase 1, Phase 2

Status

Completed

Enrollment

—

Study type

Interventional

Allocation

—

Model

—

Masking

—

Start

—

Primary completion

—

Eligibility

ALL · 18 Years · 55 Years

Interventions & indications

Drugs

Olanzapine atomoxetine

Indications

Schizophrenia Schizophrenia

Sites

20 total

Cerritos, United StatesChula Vista, United StatesGarden Grove, United StatesSan Diego, United StatesNew Haven, United StatesNew Haven, United StatesAtlanta, United StatesChicago, United StatesIndianapolis, United StatesIowa City, United StatesMinneapolis, United StatesLebanon, United States